Biocon secures USFDA approval for generic Liraglutide, entering the lucrative US obesity treatment market with gSaxenda.

Biocon Limited ( (IN:BIOCON)) just unveiled an update. Biocon Limited has increased its ownership in its unlisted material subsidiary, Biocon Biologics Limited (BBL), to around 94% of BBL’s fully ...

Biocon posts 9% rise in Q3FY26 revenue to Rs 4,173 crore; net profit jumps to Rs 143.8 crore on strong generics and ...

The market is expected to see consolidation with range-bound trading in the next few sessions. Below are some short-term trading ideas to consider.

Biocon Ltd. plans to file for regulatory approvals of generic versions of Novo Nordisk A/S's Ozempic and Wegovy in key markets as patents on the blockbuster weight-loss drugs expire next year. The ...

I write about Asia's richest, fast-growing businesses, and startups. Biocon—controlled by Indian pharmaceutical billionaire Kiran Mazumdar-Shaw—is buying the rest of privately held subsidiary Biocon ...

LA JOLLA, Calif.--(BUSINESS WIRE)-- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, ...

Zee Business analysts have shared a number of short- and long-term calls, including Tata Motors PV, Infosys, Dr Reddy’s, RVNL ...

HYDERABAD, Jan 31 (Reuters) - Indian biopharmaceutical firm Biocon (BION.NS), opens new tab is likely to list its key biosimilars business by March 2026 and aims for double-digit share in its core U.S ...

On Friday, market tech analysts Somil Mehta, Shrikant Chouhan and Mitessh Thakkar recommended these stocks for the short term.